Supriya Lifescience Limited was incorporated in 1987. However, They had started world class facilities for manufacturing API’S in 1993. In 2004, they became the globe’s top producer of chlorpheniramine maleate. Supriya Lifescience IPO will hit the market on 16 December 2021.
Table of Contents
About
Supriya Lifescience Ltd. has US FDA and EU GMP approved plant in Khed, Ratnagiri, in the sylvan outskirts of India’s Konkan area, with head office in Mumbai the financial capital of India.
Anti-Histamine, Anti-Allergic, Vitamins, and Anti-Asthmatic are few of the therapeutic sections in which they are experts. Their capacity to transform, improve & develop in a competitive and quickly growing sector & demand has established them at the top. It also enabled them reach a CAGR of 22%.
They are present in 105 countries around the world. Around 60 products in their wide portfolio of Active Pharmaceutical Ingredients have won the unconditional confidence of a committed multinational customer base.
They are certified in around 35 nations and meet the most strict quality criteria.
Clients
Global pharma businesses including Syntec Do Brasil LTDA, American International Chemical Inc, and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom they have had a nine-year business partnership, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd, and Mankind Pharma Ltd, with whom they have had a four-year business partnership.
Numerous international governing agencies have authorised their goods, including the USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA, and Taiwan FDA.
They submitted 11 active DMFs with the USFDA and seven active CEPs with EDQM for their API products in therapeutic applications like antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic, and anti-allergic.
Production plants
A modern manufacturing plant in Parshuram Lote, Maharashtra, which is roughly 250 kilometres from Mumbai, Maharashtra, supports their commercial activities.
The production plant is 23,806 square metres and has a reactor capacity of 332 kiloliters per day. They currently run five cleanrooms and are currently constructing two additional cleanrooms, which will be commercialised in the first quarter of Fiscal 2022.
The additional clean rooms will increase production capacity by 215 KL per day. In addition, their company has purchased a 12,400-square-meter block of land near its current manufacturing plant, where it plans to expand its manufacturing capability.
Supriya Lifescience IPO
Supriya Lifescience Limited, headquartered in Mumbai has submitted Draft Red Herring Prospectus(DRHP) to Securities and Exchange Board of India(SEBI) for initial public offering (IPO) of INR 1200 crore value equity shares on 15 May 2021.
The Offer includes a fresh equity of Rs. 200 crore and an offer for sale(OFS) up to Rs. 1000 crore value equity shares by the promoter Satish Waman Wagh.
They gor approval from Securities and Exchange Board of India(SEBI) to float the initial public offering (IPO) in the market on 26 July 2021.
Financials Trends
| Particulars | For the year/Period ended ( in Cr.) | |||
| 31-Dec-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
| Total Assets | 3 56.83 | 336.40 | 253.05 | 245.40 |
| Total Revenue | 267.93 | 322.71 | 285.86 | 221.51 |
| Profit After Tax | 76.19 | 73.37 | 39.42 | 8.73 |
Basic and Diluted Earnings Per Share (EPS)
| Financial Period | Basic EPS (in INR) | Diluted EPS (in INR) | Weight |
| Financial Year 2020 | 10.03 | 10.03 | 3 |
| Financial Year 2019 | 5.39 | 5.39 | 2 |
| Financial Year 2018 | 1.19 | 1.19 | 1 |
| Weighted Average | 7.01 | 7.01 | |
| (9 months) Dec. 31, 2020 | 10.41 | 10.41 | – |
Objects of the Issue
- Prepayment / repayment of all or a portion of the outstanding borrowings of the company to be availed on consolidated basis.
- To meet common corporate objectives.
Basis of The offer
- Substantial size, as well as a dominant position in main and targeted products;
- Innovative production and development and technology capacities
- Backward integrated operating system
- Good financial success over time due to a low-risk business model;
- Senior management team with significant experience and professional operating staff.
IPO Details
| IPO Opening Date | 16 December 2021 |
| IPO Closing Date | 20 December 2021 |
| Issue Type | Book Builting |
| Face Value | 2 per share |
| IPO Price | 265 to 274 per equity share |
| Market Lot | 54 |
| Min Amount | 14,796 |
| Listing At | BSE, NSE |
| Issue Size | Rs. 1,200 cr. |
| Fresh Issue | Rs. 200 Cr. |
| Offer for Sale | Rs. 1,000 Cr. |
IPO Tentative Date
The Supriya Lifescience IPO opening date is 16 December 2021, and the closing date is 20 December 2021. The issue may list on 28 December 2021.
| IPO Open Date | 16 December 2021 |
| IPO Close Date | 20 December2021 |
| Basis of Allotment Date | 23 December 2021 |
| Initiation of Refunds | 24 December 2021 |
| Credit of Shares to Demat Account | 27 December 2021 |
| IPO Listing Date | 28 December 2021 |
Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | 75 |
Roughly equivalent
|
| Non Institutional Investor | 15 |
Roughly equivalent
|
| Retail | 10 | Minimal 1 lot, based on availability. |
Supriya Lifescience IPO GMP
Supriya Lifescience IPO Grey Market Premium is INR 150.
| Date | GMP (in Rs) | Subject to Sauda | Kostak (in Rs) |
| 27 December 2021 | 150 | 2500 | 250 |
| 26 December 2021 | 100 | 1700 | 200 |
| 25 December 2021 | 110 | 2000 | 200 |
| 24 December 2021 | 115 | 3000 | 300 |
| 23 December 2021 | 145 | 5500 | 650 |
| 22 December 2021 | 86 | 3100 | 300 |
| 21 December 2021 | 90 | 4800 | 500 |
| 20 December 2021 | 175 | 3900 | 450 |
| 19 December 2021 | 225 | 4500 | 550 |
| 18 December 2021 | 204 | 3900 | 450 |
| 17 December 2021 | 225 | 3100 | 400 |
| 16 December 2021 | 275 | 6500 | 750 |
| 15 December 2021 | 255 | 5200 | 600 |
| 14 December 2021 | 265 | 5600 | 600 |
| 13 December 2021 | No Trade | No Trade | No Trade |
Supriya Lifescience IPO Review
If you are looking for answer to your question that Supriya Lifescience IPO is good or bad here is the answer, You can apply in this IPO for Listing gain as well as for long term.
Promoters of the company are very much confident about the future business and financial are also looking attractive.
Supriya Lifescience IPO Risk
- Their industry is governed by a complex set of rules.
- Any production or quality control issues could harm our reputation and subject company to lawsuits or other liabilities, thereby impacting their financial results.
- The selling of certain products accounts for a major amount of their revenue.
- A small number of clients account for a large amount of their revenue.
- Any delay in operations at, disruption or outage of, or failure to achieve optimal capacity utilisation at, their manufacturing plant could have a negative impact on their business.
- They rely on third-party vendors and carriers to a great extent. A disruption in the supply of these products could have a negative impact on their business.
Other threats
- Under their financial arrangements, their lenders have put certain restrictive limitations on them.
- Their inability to compete successfully in the pharmaceutical market may have a negative impact on their business.
- Technological advancements may render their existing technologies obsolete or necessitate significant capital investments.
- Their inability to effectively estimate demand for their items and manage their inventory could hurt their bottom line.
- The outcome of legal actions could have a negative impact on their business, operating results, and financial position.
- The COVID-19 pandemic has the potential to have a significant and negative impact on their business, financial situation, cash flows, and operating results.
Products
- Anti-Histamine
- Anti – Allergic
- Anti – Asthmatic
- Decongestant
- Analgesic / Anti-Pyretic / Anesthetic
- Vitamin
- Smoking Cessation
- Anti – Hypertensive
- Anti – Malarial
- Feed Additive
- Xanthine Derivatives & Beverages
- Phytochemical
Supriya lifescience IPO Brokerage views
- Yes Securities : Not Updated
- Choice Brokering: Not Updated
- Axis Securities: Not Updated
- IIFL Securities: Not Updated
- Trade swift: Not Updated
- Anand Rathi : Not Updated
- ICICI Securities: Not Updated
Supriya Lifescience Subscription Status
| Date | Day | QIB | NII | Retail | Employees | Total Subscription |
| 16 December 2021 | 1 | 0.00 | 0.68 | 12.24 | N/A | 2.41 |
| 17 December 2021 | 2 | 0.53 | 2.90 | 25.38 | N/A | 5.69 |
| 20 December 2021 | 3 | 31.83 | 161.22 | 56.01 | N/A | 71.51 |
Promoters
- Satish Waman Wagh
Promoter Holding
| Pre Issue Share Holding | 99.26% |
| Post Issue Share Holding |
IPO Prospectus
Contact Details
Supriya Lifescience Limited
207/208, Udyog Bhavan, Sonawala Road, Goregaon – East,
Mumbai – 400063, Maharashtra, India;
Tel: +91-22-40332727
E-mail: [email protected]
Website : www.supriyalifescience.com
Registrar
Link Intime India Private Limited
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai 400 083 Maharashtra
Tel: (+91 22) 4918 6200
E-mail: [email protected]
Website: www.linkintime.co.in
Lead Manager(s)
- ICICI Securities Limited
- Axis Capital Limited
We hope we are able to answer all you questions about Supriya Lifescience IPO. If you don’t have a Demat account, open it now with Zerodha best trading app.
FAQ
Supriya Lifescience IPO Opening Date?
Supriya Lifescience IPO will open is 16 December 2021.
Supriya Lifescience IPO Allotment Date?
Supriya Lifescience IPO Allotment Date is 23 December 2021.
Supriya Lifescience IPO Listing Date?
Supriya Lifescience IPO Listing date is 28 December 2021
Supriya Lifescience IPO GMP Today?
Supriya Lifescience IPO Grey Market Premium is INR 100.
Supriya Lifescience IPO Price Band?
Supriya Lifescience IPO price Band is 265 to 274.
